Dixon Hubard Feinour & Brown Decreased By $375,317 Its Bnc Bancorp (BNCN) Holding; Xtant Medical Holdings (NYSEMKT:XTNT) SI Decreased By 4.61%

August 29, 2017 - By Nellie Frank

Xtant Medical Holdings Incorporated (NYSEMKT:XTNT) had a decrease of 4.61% in short interest. XTNT’s SI was 1.28M shares in August as released by FINRA. Its down 4.61% from 1.34M shares previously. With 228,300 avg volume, 6 days are for Xtant Medical Holdings Incorporated (NYSEMKT:XTNT)’s short sellers to cover XTNT’s short positions. The SI to Xtant Medical Holdings Incorporated’s float is 9.46%. About 101,997 shares traded. Xtant Medical Holdings Inc (NYSEMKT:XTNT) has declined 75.28% since August 29, 2016 and is downtrending. It has underperformed by 91.98% the S&P500.

Dixon Hubard Feinour & Brown Inc decreased Bnc Bancorp (BNCN) stake by 43.57% reported in 2016Q4 SEC filing. Dixon Hubard Feinour & Brown Inc sold 12,107 shares as Bnc Bancorp (BNCN)’s stock declined 13.27%. The Dixon Hubard Feinour & Brown Inc holds 15,681 shares with $500,000 value, down from 27,788 last quarter. Bnc Bancorp now has $ valuation. It is 0.00% or $0 reaching $0 per share. It is down 39.77% since August 29, 2016 and is uptrending. It has outperformed by 23.07% the S&P500.

Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., develops, makes and markets regenerative medicine products and medical devices for domestic and international markets. The company has market cap of $12.94 million. The Firm operates through the development, manufacture and marketing of regenerative medical products and devices segment. It currently has negative earnings. The Company’s biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts.

Among 2 analysts covering Xtant Medical Holdings (NYSEMKT:XTNT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Xtant Medical Holdings had 3 analyst reports since October 23, 2015 according to SRatingsIntel. The firm has “Buy” rating by Maxim Group given on Thursday, December 8. Maxim Group maintained Xtant Medical Holdings Inc (NYSEMKT:XTNT) on Tuesday, May 23 with “Buy” rating. The company was initiated on Friday, October 23 by Brean Capital.

Investors sentiment decreased to 0.01 in 2016 Q4. Its down 0.80, from 0.81 in 2016Q3. It worsened, as 7 investors sold BNCN shares while 39 reduced holdings. 37 funds opened positions while 46 raised stakes. 28.15 million shares or 2.70% more from 27.41 million shares in 2016Q3 were reported. Massachusetts-based Panagora Asset has invested 0.01% in BNC Bancorp (NASDAQ:BNCN). Citadel Advsr Limited Liability has 20,512 shares for 0% of their portfolio. Forest Hill Cap Llc holds 2.97% of its portfolio in BNC Bancorp (NASDAQ:BNCN) for 287,750 shares. Penn Capital Mgmt Co Inc holds 0.28% or 239,810 shares. Tower Cap Llc (Trc) accumulated 886 shares. State Common Retirement Fund owns 68,277 shares. Vanguard Gru accumulated 0% or 2.60 million shares. 21,777 were accumulated by Gp. Thomson Horstmann And Bryant invested in 0.06% or 15,630 shares. Moreover, Lord Abbett And Limited Liability Corp has 0.02% invested in BNC Bancorp (NASDAQ:BNCN) for 157,200 shares. Commonwealth Equity has 13,018 shares. Kennedy Capital Incorporated holds 0.18% or 332,521 shares. Manufacturers Life The has 0% invested in BNC Bancorp (NASDAQ:BNCN). Pnc Fincl Grp Inc Inc reported 0% of its portfolio in BNC Bancorp (NASDAQ:BNCN). Moreover, Perkins Investment Management Ltd Liability has 0.32% invested in BNC Bancorp (NASDAQ:BNCN).

Since March 29, 2017, it had 0 insider buys, and 1 sale for $845,362 activity. 25,000 shares were sold by McInnis Matthew W, worth $845,362.

Among 8 analysts covering BNC Bancorp (NASDAQ:BNCN), 4 have Buy rating, 0 Sell and 4 Hold. Therefore 50% are positive. BNC Bancorp had 13 analyst reports since October 13, 2015 according to SRatingsIntel. Gabelli downgraded the shares of BNCN in report on Tuesday, August 9 to “Hold” rating. Piper Jaffray initiated the stock with “Overweight” rating in Wednesday, November 16 report. The rating was downgraded by Sandler O’Neill on Tuesday, November 22 to “Hold”. The rating was downgraded by Raymond James on Monday, October 26 to “Market Perform”. Stephens initiated it with “Overweight” rating and $29.50 target in Wednesday, December 2 report. The firm has “Buy” rating by Gabelli given on Tuesday, January 26. As per Monday, May 9, the company rating was upgraded by Raymond James. The firm has “Market Perform” rating given on Tuesday, October 13 by Hovde Group. Keefe Bruyette & Woods downgraded the shares of BNCN in report on Tuesday, November 29 to “Mkt Perform” rating.